Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.

The pharmacogenomics journal - 1 Apr 2019

Girardin François R, Poncet Antoine, Perrier Arnaud, Vernaz Nathalie, Pletscher Mark, F Samer Caroline, Lieberman Jeffrey A, Villard Jean

Abstract excerpt

Less than 1% of adult patients with schizophrenia taking clozapine develop agranulocytosis, and most of these cases occur within the first weeks of treatment. The human leukocyte antigen (HLA) region has been associated with genetic susceptibility to clozapine-induced agranulocytosis (single amino acid changes in HLA-DQB1 (126Q) and HLA-B (158T)). The current study aimed to evaluate the cost-effectiveness, from a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Clozapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cost-Benefit Analysis

Share to HLA-B Antigens

Share to HLA-DQ beta-Chains

Share to Pharmacogenomic Testing

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 29298994
DOI: 10.1038/s41397-017-0004-2
PMCID: PMC6462824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.PMID 29298994Read ↗

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.Semantic proximity Read ↗

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.Semantic proximity Read ↗

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and AgranulocytosisSemantic proximity Read ↗

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of antipsychotics: recent progress and methodological issuesSemantic proximity Read ↗

Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.Semantic proximity Read ↗

Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkSemantic proximity Read ↗

Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C.Semantic proximity Read ↗

Predicting agranulocytosis in patients treated with clozapine – development and validation of a machine learning algorithm based on 5,550 patientsSemantic proximity Read ↗

ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia.Semantic proximity Read ↗

Pharmacogenetic Testing in the Clinical Management of SchizophreniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.